AstraZeneca Mulls Spinning Off Its China Business and Listing It in Hong Kong AstraZeneca, the global pharmaceutical giant, is reportedly considering a plan to spin off its China business and list it as a separate entity in Hong Kong, according to the Financial Times. The move could help the company navigate the complex and competitive Chinese market, while avoiding potential geopolitical risks. AstraZeneca is one of the leading drugmakers in China, with a 13% share of its total sales in 2020. The company has a strong presence in the fields of oncology, cardiovascular, renal and metabolism, respiratory and immunology. It has also been involved in the development and distribution of COVID-19 vaccines in collaboration with Oxford University. However, the company also faces challenges in China, such as regulatory hurdles, pricing pressures, local competition and political tensions. A spin off could allow AstraZeneca to retain control of its China business, while giving it more...